Parliamentary Search

Written question asked by Lola McEvoy (Labour) on Monday, 13 July 2026, in the House of Commons. It was due for an answer on Wednesday, 15 July 2026. It was answered by Preet Kaur Gill (Labour) on Monday, 20 July 2026 on behalf of the Department of Health and Social Care.

Clozapine

Question

To ask the Secretary of State for Health and Social Care, what steps the MHRA intends to take to consider patient and bereaved family lived experience as part of its current scientific review of Clozapine; and whether he is taking steps to ensure that lived experience actively shapes the committee's clinical determinations before key regulatory decisions have been made.

Answer

The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the requirements for this type of monitoring. At present, clozapine drug-level monitoring is required only in specific clinical situations, partly because of the high level of variability between patients. The MHRA is taking forward the NPPEAG’s recommendations and will communicate to healthcare professionals once the regulatory position is finalised.

The review of clozapine drug-level monitoring focused on clinical and scientific data to establish the value of this type of monitoring in clinical practice. It took into account a range of information, including overall reporting patterns and themes in reports received through the Yellow Card scheme, but did not include clinical review of individual Yellow Card reports. MHRA safety assessments may also consider the views of patients and other stakeholders.

The MHRA will be launching a survey in the summer to gather information on awareness of key risks associated with clozapine, and to assess whether additional measures would be helpful for patients, their families, and carers, as well as healthcare professionals involved in the care of patients receiving clozapine.

Secondary information

Type
Written question
Reference
18199
Session
2026-27
Grouped for answer
Yes
Subjects
Standards Safety Clozapine
Link
View this Written question on www.parliament.uk